Company / EPS (Basic)
Spero Therapeutics, Inc. EPS (Basic) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.27
FY2025
5-year range
-$2.91 / $0.43
FY2022-FY2025
Trend
-395.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) changed -395% YoY in FY2025, a notable deviation from the 3-year average annual change of -68%.
Based on SEC 10-K filings.
-1.27 in FY2025.
Declined from $-1.23 to $-1.27 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (basic) decreased 395.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.27 | -395.3% |
| FY2024 | $0.43 | +135.0% |
| FY2023 | -$1.23 | +57.7% |
| FY2022 | -$2.91 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026